Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8392)	1/20/1999 5:11:00 PM
From: Tharos	Respond to of 17367

Nice find. Also nice to see they are once again studying BPI over here. They probably have been all along, but ever since the halt of the E5 trial BPI has not been in the magazines. I will try and track down more on Hanasawa and Kodama.

To: Cacaito who wrote (8392)	1/21/1999 5:40:00 AM
From: Robert S.	Respond to of 17367

Interesting abstract, Cacaito, but I am aghast that you would reference a mere review. Japanese review mentioned Bpi as "potential". Didn't BPI first exhibit "potential" in 1978?

To: Cacaito who wrote (8392)	1/21/1999 7:32:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

There is a pertinent article in today NEJM about ideas to treat severe sepsis. As you know NEJM is well read. I cant read the article yet so I dont know if we will get a mention or not. Someone post if we do or dont. Here is a recent listing of some therapies in trial (not from todays article) > Some therapeutic interventions in sepsis undergoing clinical trials Lipopolysaccharide analogues High-density lipoprotein Haemoperfusion with polymyxin B Polymyxin B linked to dextran Bactericidal permeability increasing protein Anti-TNF antibodies TNF receptor p55 Corticosteroids Inhibitors of nitric-oxide (NO) synthase Haemoglobin solutions (as NO scavengers) Granulocyte-colony-stimulating factor Antithrombin III, activated factor C, tissue-factor-pathway inhibitor Antioxidants (procysteine) Immunonutrition (fish oil, antioxidants) Lisofylline (anti-TNF agent) Recombinant platelet-activating-factor inhibitor